# FDA places Regenxbio's Hunter syndrome gene therapy on clinical hold

_Published Tuesday, August 25, 2026 at 12:19 PM EDT · Policy · Latest · Tier 2 — Notable_

![Wide landscape preview. — Primary](https://etimg.etb2bimg.com/thumb/msid-133510617,imgsize-1132487,width-1200,height=627,overlay-etpharma,resizemode-75/news/pharma-industry/fda-places-clinical-hold-on-regenxbios-gene-therapy-for-hunter-syndrome.jpg)

The FDA has placed Regenxbio's experimental RGX-121 gene therapy for Hunter syndrome on clinical hold, Regenxbio said, after spinal scans found abnormalities in five study participants. The company said the affected patients had received the treatment about three to six years earlier. RGX-121 uses an AAV9 vector to deliver a gene intended to produce a missing enzyme. Regenxbio and partner NS Pharma plan to review additional imaging and longer-term follow-up data while awaiting the agency's full hold letter.

## Sources

- [pharma.economictimes.indiatimes.com](https://pharma.economictimes.indiatimes.com/news/pharma-industry/fda-places-clinical-hold-on-regenxbios-gene-therapy-for-hunter-syndrome/133510617)

---
Canonical: https://techandbusiness.org/newswire/Oz5xB4p6t2DIsWmTNokNTf
Published: 2026-08-25T16:19:07.741Z
Story chronology: 2026-08-25T12:33:43.000Z
Retrieved: 2026-10-09T19:41:32.551Z
Publisher: Tech & Business (techandbusiness.org)